JP2024521861A - 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法 - Google Patents

抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法 Download PDF

Info

Publication number
JP2024521861A
JP2024521861A JP2023573437A JP2023573437A JP2024521861A JP 2024521861 A JP2024521861 A JP 2024521861A JP 2023573437 A JP2023573437 A JP 2023573437A JP 2023573437 A JP2023573437 A JP 2023573437A JP 2024521861 A JP2024521861 A JP 2024521861A
Authority
JP
Japan
Prior art keywords
cells
antibody
agents
agent
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573437A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022248940A5 (https=
JP2024521861A5 (https=
Inventor
ニコラ・ポワリエ
イレーヌ・バチェッリ
カロリーヌ・マリー
サブリナ・パンガム
Original Assignee
オーエスイー・イミュノセラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーエスイー・イミュノセラピューティクス filed Critical オーエスイー・イミュノセラピューティクス
Publication of JP2024521861A publication Critical patent/JP2024521861A/ja
Publication of JPWO2022248940A5 publication Critical patent/JPWO2022248940A5/ja
Publication of JP2024521861A5 publication Critical patent/JP2024521861A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023573437A 2021-05-28 2022-05-27 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法 Pending JP2024521861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/334,158 2021-05-28
US17/334,158 US20220389104A1 (en) 2021-05-28 2021-05-28 Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
PCT/IB2022/000365 WO2022248940A1 (en) 2021-05-28 2022-05-27 Method for treating cd127-positive cancers by administering an anti-cd127 agent

Publications (3)

Publication Number Publication Date
JP2024521861A true JP2024521861A (ja) 2024-06-04
JPWO2022248940A5 JPWO2022248940A5 (https=) 2025-06-03
JP2024521861A5 JP2024521861A5 (https=) 2025-06-03

Family

ID=82701915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573437A Pending JP2024521861A (ja) 2021-05-28 2022-05-27 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法

Country Status (5)

Country Link
US (1) US20220389104A1 (https=)
EP (1) EP4347043A1 (https=)
JP (1) JP2024521861A (https=)
CN (1) CN117769435A (https=)
WO (1) WO2022248940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
MX339083B (es) * 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016059220A1 (en) * 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
WO2017005919A1 (en) * 2015-07-08 2017-01-12 Biomedical Research Foundation Of The Academy Of Athens Novel compounds for use in treating or preventing cancerous diseases
EP3355875B1 (en) * 2015-10-01 2021-09-29 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AU2016335750B2 (en) * 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017149394A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
DK3551664T3 (da) 2016-12-09 2021-05-03 Ose Immunotherapeutics Antistoffer og polypeptider rettet mod cd127
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof

Also Published As

Publication number Publication date
EP4347043A1 (en) 2024-04-10
CN117769435A (zh) 2024-03-26
WO2022248940A1 (en) 2022-12-01
US20220389104A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
TWI725966B (zh) 癌症組合療法
JP6875295B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
JP6588461B2 (ja) 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
EP3419999B1 (en) Antibodies having specificity for btla and uses thereof
RU2519669C2 (ru) Лечение антителами против vegf
US10899840B2 (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3589654A1 (en) Antibodies having specificity to nectin-4 and uses thereof
TW201615212A (zh) 用於治療癌症之ｐｄ－１拮抗劑及ｖｅｇｆｒ抑制劑之組合
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
US10398774B2 (en) Human monoclonal antibodies against AXL
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
TW202038975A (zh) 多發性骨髓瘤之組合治療
JP2024521861A (ja) 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法
CA3224693A1 (en) Anti-tnfr2 antibody and uses thereof
EP3800201A1 (en) Cd28h stimulation enhances nk cell killing activities
US11186634B2 (en) Antibodies targeting tumor associated macrophages and uses thereof
US20230227565A1 (en) Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2024052503A1 (en) Antibodies having specificity to ltbp2 and uses thereof
US20230181753A1 (en) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
JP2023512151A (ja) Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法
WO2024161015A1 (en) Method to treat age-related diseases
JP2024515211A (ja) Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強
WO2025224297A1 (en) Antibodies having specificity to tgfbi and uses thereof

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523